A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors

Cancer

Volumn 118, Issue 17, 2012, Pages 4262-4270

  Rocha Lima, Caio M ^a   Bayraktar, Soley ^b   MacIntyre, Jessica ^a   Raez, Luis ^a   Flores, Aurea M ^a   Ferrell, Annapoorna ^c   Rubin, Eric H ^d   Poplin, Elizabeth A ^e   Tan, Antoinette R ^e   Lucarelli, Antonio ^f   Zojwalla, Naseem ^f  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^f EISAI INC   (United States)

Author keywords

antitubulin resistance; E7974; hemiasterlin; maximal tolerated dose; refractory solid tumors; toxicity profile

Indexed keywords

ANTINEOPLASTIC AGENT; E 7974; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG URINE LEVEL; DRY SKIN; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HEMATOLOGIC DISEASE; HUMAN; HYPOMAGNESEMIA; LEUKOPENIA; LIPOSARCOMA; LUNG CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PARESTHESIA; PAROTID GLAND CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; SOLID TUMOR; SURVIVAL TIME; THYMOMA; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMITOTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; OLIGOPEPTIDES; PIPERIDINES; TREATMENT OUTCOME;

EID: 84865335243     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27428     Document Type: Article

References (46)

1. Harker WG, MacKintosh FR, Sikic BI,. Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. Cancer Res. 1983; 43: 4943-4950.
2. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 1997; 272: 17118-17125.
3. Chen G, Duran GE, Steger KA, et al. Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J Biol Chem. 1997; 272: 5974-5982.
4. Sale S, Sung R, Shen P, et al. Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther. 2002; 1: 215-225.
5. Giodini A, Kallio MJ, Wall NR, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 2002; 62: 2462-2467.
6. Nicoletti MI, Valoti G, Giannakakou P, et al. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Clin Cancer Res. 2001; 7: 2912-2922.
7. Shan B, Medina JC, Santha E, et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci U S A. 1999; 96: 5686-5691.
8. Anderson HJ, Coleman JE, Andersen RJ, Roberge M,. Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Cancer Chemother Pharmacol. 1997; 39: 223-226.
9. Kowalczyk JJ, Schiller SER, Spyvee M, et al. Synthetic analogs of the marine natural product hemiasterlin: optimization and discovery of E7974, a novel and potent antitumor agent [abstract]. Proc Am Assoc Cancer Res. 2005; 46. Abstract 1212.
10. Ratain MJ, Vogelzang NJ,. Phase I and pharmacological study of vinblastine by prolonged continuous infusion. Cancer Res. 1986; 46: 4827-4830.
11. Bai R, Durso NA, Sackett DL, Hamel E,. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. Biochemistry. 1999; 38: 14302-14310.
12. Gamble WR, Durso NA, Fuller RW, et al. Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalina spp. sponges. Bioorg Med Chem. 1999; 7: 1611-1615.
13. Coleman JE, Kong F, Andersen RJ, Allen TM,. Cytotoxic peptides from the marine sponge Cymbastela sp. Tetrahedron. 1995; 51: 10653-10662.
14. Kuznetsov G, TenDyke K, Towle MJ, et al. Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Mol Cancer Ther. 2009; 8: 2852-2860.
15. Fojo T, Poruchynsky M, Giannakakou P, et al. Microtubules as chemotherapy agents: still exciting. Paper presented at: Centro Nacional de Investigaciones Oncologicas-National Cancer Institute (CNIO-NCI) Meeting; June 26-27, 2003; Madrid, Spain.
16. Bradbury DA, Simmons TD, Slater KJ, Crouch SP,. Measurement of the ADP:ATP ratio in human leukaemic cell lines can be used as an indicator of cell viability, necrosis and apoptosis. J Immunol Methods. 2000; 240: 79-92.
17. Crouch SP, Slater KJ, Fletcher J,. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Meth. 1993; 160: 81-88.
18. Liu A, Bernhard EJ, Prendergast GC,. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proc Natl Acad Sci U S A. 2001; 98: 6192-6197.
19. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C,. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991; 139: 271-279.
20. Salvesen GS, Dixit VM,. Caspases: intracellular signaling by proteolysis. Cell. 1997; 91: 443-446.
21. Smulson ME, Simbulan-Rosenthal CM, Boulares AH, et al. Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1. Adv Enzyme Regul. 2000; 40: 183-215.
22. Thornberry NA, Lazebnik Y,. Caspases: enemies within. Science. 1998; 281: 1312-1316.
23. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS,. Effect of p53 status on tumor response to antiangiogenic therapy. Science. 2002; 295: 1526-1528.
24. Powolny A, Xu J, Loo G,. Deoxycholate induces DNA damage and apoptosis in human colon epithelial cells expressing either mutant or wild-type p53. Int J Biochem Cell Biol. 2001; 33: 193-203.
25. Kuznetsov G, Liu J, Cheng H, et al. Tubulin-based antimitotic mechanism of novel hemiasterlin analog E7974. Proc Am Assoc Cancer Res. 2005; 46: 2852- 2860.
26. Kuznetsov G, Towle MJ, Cheng H, et al. In vitro and in vivo antitumor activities of novel hemiasterlin analog E7974. Proc Am Assoc Cancer Res. 2005: 18-22.
27. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998; 352: 1413-1418.
28. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2002; 20: 165-172.
29. Van Cutsem E, Osterwalder B, Kocha W, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000; 18: 1337-1345.
30. Uchiyama-Kokubu N, Watanabe T,. Establishment and characterization of Adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance. Anticancer Drugs. 2001; 12: 769-779.
31. Gemzar (gemcitabine HCl) [package insert]. Indianapolis, IN: Eli Lilly and Company; 1998.
32. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996; 7: 347-353.
33. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999; 17: 485-493.
34. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001; 92: 1759-1768.
35. Degardin M, Bonneterre J, Hecquet B, et al. Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol. 1994; 5: 423-426.
36. Gelmon K, Eisenhauer E, Bryce C, et al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol. 1999; 17: 3038-3047.
37. Tolcher AW, Sugarman S, Gelmon KA, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 1999; 17: 478-484.
38. Hu Z, Sun Y, Garen A,. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci U S A. 1999; 96: 8161-8166.
39. Dimasi JA,. New drug development in the United States from 1963 to 1999. Clin Pharmacol Ther. 2001; 69: 286-296.
40. Dimasi JA,. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther. 2001; 69: 297-307.
41. Buyse M,. Randomized designs for early trials of new cancer treatments: an overview. Drug Information J. 2000; 34: 387-396.
42. Therasse P, Eisenhauer EA, Verweij J,. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006; 42: 1031-1039.
43. Naoto MS, Takahiro K,. The efficacy and toxicity of taxanes in patients with metastatic breast cancer receiving prior chemotherapy. Jpn J Breast Cancer. 2004; 19: 232-238.
44. Loibl S, Elling D, Janni W, et al. Toxicity in elderly breast cancer patients treated by a taxane based chemotherapy as adjuvant or neoadjuvant therapy for primary breast cancer. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2006; Atlanta, Ga.
45. Madajewicz S, Lucarelli AG, Hentschel P, et al. A phase I trial of E7974 administered on days 1 and 15 of a 28-day cycle in patients with solid malignancies. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, Ill.
46. Zojwalla NJ, Lucarelli AG, Clark R, et al. A phase I trial of E7974 administered on days 1, 8, and 15 of a 28-day cycle in patients with solid malignancies. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, Ill.